abstract |
The invention relates to nicotinamide mononucleotide, one of the pharmaceutically acceptable derivatives thereof, one of the pharmaceutically acceptable precursors thereof or one of the pharmaceutically acceptable salts thereof, for use in reducing immunosenescence and/or enhancing immune response to vaccination, and further relates to compositions containing same. |